PLK1在不同TP53基因型宫颈癌细胞中的作用

孟繁杰 ,  周丽 ,  邢思宁 ,  于卉影

中国医科大学学报 ›› 2026, Vol. 55 ›› Issue (8) : 687 -692.

PDF (713KB)
中国医科大学学报 ›› 2026, Vol. 55 ›› Issue (8) : 687 -692. DOI: 10.12007/j.issn.0258‐4646.2026.08.003
论著

PLK1在不同TP53基因型宫颈癌细胞中的作用

作者信息 +

Effect of PLK1 on cervical cancer cells with different TP53 genotypes

Author information +
文章历史 +
PDF (729K)

摘要

目的 探讨Polo样激酶1 (PLK1) 在不同TP53基因型宫颈癌细胞中的作用。方法 用0 (对照组)、2.5 (低浓度组)、5 nmol/L (高浓度组) PLK1抑制剂GSK461364分别处理TP53突变型宫颈癌C33a细胞和TP53野生型宫颈癌SiHa细胞24 h,检测细胞增殖、细胞周期、细胞干性和细胞周期相关蛋白表达变化。结合GEPIA和TCGA数据库,分析PLK1表达水平及其临床意义。结果 GSK461364处理后,C33a细胞增殖被抑制,C33a细胞和SiHa细胞均发生G2期细胞周期阻滞,细胞成球能力均下降。C33a细胞中,低浓度组、高浓度组细胞周期相关蛋白P-cdc25c、cdc25c、E2F-1表达显著下调 (P < 0.05),高浓度组转录因子FoxO1表达水平显著降低 (P < 0.05)。SiHa细胞中,高浓度组细胞周期相关蛋白P-cdc25c、E2F-1表达显著下调 (P < 0.05),转录因子FoxO1表达水平显著降低 (P < 0.05)。PLK1在宫颈癌患者中呈高表达;PLK1低表达的宫颈癌患者与PLK1高表达的宫颈癌患者相比,FoxO1低表达的宫颈癌患者与FoxO1高表达的宫颈癌患者相比,无进展生存期均显著延长 (P < 0.05)。结论 PLK1 抑制剂影响宫颈癌细胞增殖、细胞周期、细胞成球能力,且在不同TP53基因型的宫颈癌细胞中作用不同。

Abstract

Objective To investigate the role of Polo-like kinase 1 (PLK1) in cervical cancer cells with different TP53 genotypes. Methods C33a cells (TP53 mutant type) and SiHa cells (TP53 wild type) were treated with the PLK1 inhibitor GSK461364 at 0 nmol/L (control group),2.5 nmol/L (low-concentration group),or 5 nmol/L (high-concentration group) for 24 h. Cell proliferation,cell cycle distribution,stemness,and the expression of cell cycle-related proteins were assessed. GEPIA and TCGA databases were used to analyze PLK1 expression and its clinical significance. Results GSK461364 inhibited C33a cell proliferation,induced G2-phase arrest in both cell lines,and attenuated spheroid formation capacity. In C33a cells,both the low- and high-concentration groups showed significantly decreased expression of P-cdc25c,cdc25c,and E2F-1 (P < 0.05),whereas FoxO1 expression was significantly decreased only in the high-concentration group (P < 0.05). In SiHa cells,the high-concentration group showed significantly downregulated expression of P-cdc25c,E2F-1,and FoxO1 (P < 0.05). PLK1 was highly expressed in cervical cancer. Patients with low PLK1 or FoxO1 expression exhibited significantly longer progression-free survival than those with high expression (P < 0.05). Conclusion PLK1 inhibition suppressed cell proliferation,induced cell cycle arrest,and impaired spheroid formation in cervical cancer cells,with differential effects according to TP53 genotype.

关键词

Polo样激酶1 / 宫颈癌 / 细胞增殖 / 细胞周期

Key words

Polo-like kinase 1 / cervical cancer / cell proliferation / cell cycle

引用本文

引用格式 ▾
孟繁杰,周丽,邢思宁,于卉影. PLK1在不同TP53基因型宫颈癌细胞中的作用[J]. 中国医科大学学报, 2026, 55(8): 687-692 DOI:10.12007/j.issn.0258‐4646.2026.08.003

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

JHA AK,MITHUN S,SHERKHANE UB,et al. Systematic review and meta-analysis of prediction models used in cervical cancer [J]. Artif Intell Med,2023,139:102549. DOI:10.1016/j.artmed.2023.102549.

[2]

BUSKWOFIE A,DAVID-WEST G,CLARE CA. A review of cervical cancer:incidence and disparities [J]. J Natl Med Assoc,2020,112 (2):229-232. DOI:10.1016/j.jnma.2020.03.002.

[3]

LIZANO M,CARRILLO-GARCÍA A,DE LA CRUZ-HERNÁNDEZ E,et al. Promising predictive molecular biomarkers for cervical cancer (Review) [J]. Int J Mol Med,2024,53 (6):50. DOI:10.3892/ijmm.2024.5374.

[4]

MARQUINA G,MANZANO A,CASADO A. Targeted agents in cervical cancer:beyond bevacizumab [J]. Curr Oncol Rep,2018,20 (5):40. DOI:10.1007/s11912-018-0680-3.

[5]

ZHU H,LUO H,ZHANG W,et al. Molecular mechanisms of cisplatin resistance in cervical cancer [J]. Drug Des Dev Ther,2016,10:1885-1895. DOI:10.2147/DDDT.S106412.

[6]

HU J,CAO J,TOPATANA W,et al. Targeting mutant p53 for cancer therapy:direct and indirect strategies [J]. J Hematol Oncol,2021,14 (1):157. DOI:10.1186/s13045-021-01169-0.

[7]

LIU Y,SU Z,TAVANA O,et al. Understanding the complexity of p53 in a new era of tumor suppression [J]. Cancer Cell,2024,42 (6):946-967. DOI:10.1016/j.ccell.2024.04.009.

[8]

SONG C,ZHANG M,KRUSE T,et al. Self-priming of Plk1 binding to BubR1 ensures accurate mitotic progression [J]. Commun Biol,2024,7:1473. DOI:10.1038/s42003-024-07205-2.

[9]

GAO L,PANG YY,GUO XY,et al. Polo like kinase 1 expression in cervical cancer tissues generated from multiple detection methods [J]. PeerJ,2020,8:e10458. DOI:10.7717/peerj.10458.

[10]

MENG F,YAN Y,ZHOU L,et al. Targeting autophagy promotes the antitumor effect of radiotherapy on cervical cancer cells [J]. Cancer Biol Ther,2024,25 (1):2431136. DOI:10.1080/15384047.2024.2431136.

[11]

孟繁杰,阎英,熊婵,等. 自噬和衰老在放射诱导的多倍体宫颈癌细胞中的作用 [J]. 肿瘤预防与治疗,2022,35 (6):493-499. DOI:10.3969/j.issn.1674-0904.2022.06.001.

[12]

BELLAH SF,XIONG F,DOU Z,et al. PLK1 phosphorylation of ZW10 guides accurate chromosome segregation in mitosis [J]. J Mol Cell Biol,2024,16 (2):mjae008. DOI:10.1093/jmcb/mjae008.

[13]

HERTEL A,STORCHOVÁ Z. The role of p53 mutations in early and late response to mitotic aberrations [J]. Biomolecules,2025,15 (2):244. DOI:10.3390/biom15020244.

[14]

SHI F,LI T,LIU Z,et al. FOXO1:another avenue for treating digestive malignancy [J]. Semin Cancer Biol,2018,50:124-131. DOI:10.1016/j.semcancer.2017.09.009.

[15]

XU Z,GUAN L,WANG Y,et al. Discovery of a novel PLK1 inhibitor with high inhibitory potency using a combined virtual screening strategy [J]. J Enzyme Inhib Med Chem,2025,40 (1):2467798. DOI:10.1080/14756366.2025.2467798.

基金资助

辽宁省科学技术计划(2023-MS-037)

沈阳市科技计划(24-214-3-173)

AI Summary AI Mindmap
PDF (713KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉